Volumetric modulated arc therapy treatment planning based on virtual monochromatic images for head and neck cancer: effect of the contrast‐enhanced agent on dose distribution

DOI Web Site Web Site Web Site Web Site ほか1件をすべて表示 一部だけ表示 参考文献27件 オープンアクセス
  • Riho Komiyama
    Department of Radiation Oncology Osaka International Cancer Institute Osaka Japan
  • Shingo Ohira
    Department of Radiation Oncology Osaka International Cancer Institute Osaka Japan
  • Naoyuki Kanayama
    Department of Radiation Oncology Osaka International Cancer Institute Osaka Japan
  • Tsukasa Karino
    Department of Radiation Oncology Osaka International Cancer Institute Osaka Japan
  • Hayate Washio
    Department of Radiation Oncology Osaka International Cancer Institute Osaka Japan
  • Yoshihiro Ueda
    Department of Radiation Oncology Osaka International Cancer Institute Osaka Japan
  • Masayoshi Miyazaki
    Department of Radiation Oncology Osaka International Cancer Institute Osaka Japan
  • Teruki Teshima
    Department of Radiation Oncology Osaka International Cancer Institute Osaka Japan

この論文をさがす

説明

<jats:title>Abstract</jats:title><jats:p>Virtual monochromatic images (VMIs) at a lower energy level can improve image quality but the computed tomography (CT) number of iodine contained in the contrast‐enhanced agent is dramatically increased. We assessed the effect of the use of contrast‐enhanced agent on the dose distributions in volumetric modulated arc therapy (VMAT) planning for head and neck cancer (HNC). Based on the VMIs at 40 keV (VMI<jats:sub>40keV</jats:sub>), 60 keV(VMI<jats:sub>60keV</jats:sub>), and 77 keV (VMI<jats:sub>77keV</jats:sub>) of a tissue characterization phantom, lookup tables (LUTs) were created. VMAT plans were generated for 15 HNC patients based on contrast‐enhanced‐ (CE‐) VMIs at 40‐, 60‐, and 77 keV using the corresponding LUTs, and the doses were recalculated based on the noncontrast‐enhanced‐ (nCE‐) VMIs. For all structures, the difference in CT numbers owing to the contrast‐enhanced agent was prominent as the energy level of the VMI decreased, and the mean differences in CT number between CE‐ and nCE‐VMI was the largest for the clinical target volume (CTV) (125.3, 55.9, and 33.1 HU for VMI<jats:sub>40keV</jats:sub>, VMI<jats:sub>60keV</jats:sub>, and VMI<jats:sub>77keV,</jats:sub> respectively). The mean difference of the dosimetric parameters (D<jats:sub>99%</jats:sub>, D<jats:sub>50%</jats:sub>, D<jats:sub>1%</jats:sub>, D<jats:sub>mean</jats:sub>, and D<jats:sub>0.1cc</jats:sub>) for CTV and OARs was <1% in the treatment plans based on all VMIs. The maximum difference was observed for CTV in VMI<jats:sub>40keV</jats:sub> (2.4%), VMI<jats:sub>60keV</jats:sub> (1.9%), and VMI<jats:sub>77keV</jats:sub> (1.5%) plans. The effect of the contrast‐enhanced agent was larger in the VMAT plans based on the VMI at a lower energy level for HNC patients. This effect is not desirable in a treatment planning procedure.</jats:p>

収録刊行物

参考文献 (27)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

問題の指摘

ページトップへ